Research Paper Background Section Outline I. Defining Vasoplegia: Vasoplegic syndrome is defined as significant hypotension, normal or high cardiac

Research Paper Background Section Outline

I. Defining Vasoplegia: Vasoplegic syndrome is defined as significant hypotension, normal or high cardiac output, and low systemic vascular resistance (SVR) that does not respond to volume or vasopressor use. The majority of literature on vasoplegia surrounds cardiac surgery and there is limited data found in liver transplantation.

II. Vasoplegia in liver transplant and the common treatment option: vasopressors, methylene blue, and hydroxocobalamin (mechanism of action of Vasoplegia in liver transplant, how common, etc.)

III. Treatment of refractory Vasoplegia. Mechanism of action of methylene blue versus hydroxocobalamin for Vasoplegia. Case reports (case reports attached) on the use of methylene blue compared to hydroxocobalamin for the management of Vasoplegia in both cardiac surgery and liver transplant. Include adverse effects and contraindications to both methylene blue and hydroxocobalamin.

IV. There is little data to be found exclusively on hydroxocobalamin for the treatment of vasoplegia in liver transplantation. Specifically state the case report data on hydroxocobalamin exclusively in liver transplant (case reports attached).